HER2+ Breast Cancer | Specialty

The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.

Utilizing pCR in Breast Cancer Trials

August 7th 2014

Upfront T-DM1 in HER2-Positive Breast Cancer

August 7th 2014

HER2 Testing Challenges in Metastatic Breast Cancer

August 7th 2014

First-Line Treatment of HER2-Positive MBC

August 7th 2014

Exceptional Responders in Breast Cancer

August 7th 2014

Nab-Paclitaxel in Metastatic Breast Cancer

August 7th 2014

Introduction: Chemotherapies for Advanced Breast Cancer

August 7th 2014

Evolving Therapeutic Landscape in Breast Cancer

August 5th 2014

Case Studies: Treating Metastatic Breast Cancer

August 5th 2014

Clinical Setting for Eribulin in Metastatic Breast Cancer

August 5th 2014

Treatment Strategies in ER-Positive Breast Cancer

August 5th 2014

First-Line ER-Positive MBC Treatments

August 5th 2014

Changing Treatment Landscape in Metastatic Breast Cancer

August 5th 2014

Extended Adjuvant Neratinib Improves DFS in Phase III Breast Cancer Study

July 23rd 2014

Extended adjuvant treatment with neratinib (PB272, HKI-272) significantly extended improved disease-free survival (DFS) compared with placebo for patients with HER2-positive breast cancer who received prior adjuvant trastuzumab

Dr. Tripathy on Decision-Making for Sequencing Therapies for HER2-Positive MBC

July 18th 2014

Debu Tripathy, MD, discusses a decision-making framework for sequencing therapies for HER2-positive metastatic breast cancer.

Risk of Recurrence Low in Small, HER2-Positive Breast Tumors

July 15th 2014

Patients with small, node-negative, HER2-positive breast cancer tumors had a low risk of invasive recurrence after 5 years

T-DM1 Poised to Set New Standard in HER2-Positive Metastatic Breast Cancer

July 14th 2014

The antibody-drug conjugate T-DM1 (ado-trastuzumab emtansine; Kadcyla) will have an impact on the entire spectrum of care for patients with metastatic HER2-positive breast cancer, resulting in a greater emphasis on patient selection protocols and testing.

Trastuzumab-Associated Cardiac Events Reversible, Outweighed by Benefits

July 14th 2014

Cardiac events associated with trastuzumab are mostly reversible and outweighed by significant extensions in OS and PFS for patients with HER2-positive breast cancer, according to analyses from several clinical trials exploring the drug.

Dr. Brufsky on Trastuzumab and Eribulin for HER2+ Metastatic Breast Cancer

July 11th 2014

Adam M. Brufsky, MD, PhD, discusses the effect of prior trastuzumab on eribulin mesylate in combination with trastuzumab as first-line treatment for HER2-positive locally recurrent or metastatic breast cancer.

Dr. Kirkman on the Novel HER2-Specific Inhibitor ONT-380 for Breast Cancer

June 24th 2014

Robert L. Kirkman, MD, President and CEO, Oncothyreon, discusses the evaluation of ONT-380, an oral HER2-specific inhibitor, for the treatment of patents with HER2-positive metastatic breast cancer.